STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
A biotech company called Vaxcyte has announced that its experimental vaccine against pneumococcal disease met its main goals in late-stage clinical testing. This result positions Vaxcyte to compete with larger pharmaceutical companies Pfizer and Merck in the vaccine market for this disease. The successful trial results could help Vaxcyte move toward getting regulatory approval to sell the vaccine.
3 across the spectrum. Choose a side on the bar to jump to it.
National story. 4 articles from 3 sources. Updated 7d ago.
How each side is putting it
Left
1 viewpointVaxcyte stock surged after its pneumococcal vaccine passed a key phase 3 test
Center
1 viewpointRight
1 viewpointVaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study